1,405 results on '"Sparano, Joseph A"'
Search Results
152. Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
153. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103
154. A 21-Gene Expression Assay in Breast Cancer
155. Increasing the Efficacy of 5-Fluorouracil with Interferons: Preclinical, Clinical, and Pharmacokinetic Studies
156. Clinical Studies Examining the Impact of Obesity on Breast Cancer Risk and Prognosis
157. Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
158. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
159. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
160. Clinical Application of Gene Expression Profiling in Breast Cancer
161. Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma
162. Tumor Microenvironment of Metastasis and Risk of Distant Metastasis of Breast Cancer
163. Reply to T. Shimoi et al and Y. Shimanuki et al
164. Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
165. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
166. Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy
167. Seroconversion rates following COVID-19 vaccination among patients with cancer
168. Abstract 35: Racial disparity in localized breast cancer: Pooled analysis of NSABP trials
169. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy
170. Chemotherapy in Patients with Anthracycline and Taxane-Pretreated Metastatic Breast Cancer: An Overview
171. How Do I Treat Inflammatory Breast Cancer?
172. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease
173. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials
174. Reply to K. Ando et al
175. Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer
176. Prospective validation of genetic predictors of aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) in a racially diverse cohort: Results from ECOG-ACRIN E1Z11.
177. Predictors of surgery preference and quality of life in DCIS after breast MRI: A trial of the ECOG-ACRIN Cancer Research Group (E4112).
178. A simulation model-based clinical decision tool to guide personalized treatment based on individual characteristics: Does 21-gene recurrence score assay testing change decisions?
179. A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131
180. Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial.
181. Expanding Criteria for Prognostic Stage IA in Hormone Receptor–Positive Breast Cancer
182. Seroconversion rates following COVID-19 vaccination amongst patients with malignant disease- the impact of diagnosis and cancer-directed therapies
183. Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
184. Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG‐ACRIN TAILORx trial
185. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer
186. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study
187. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
188. GRB7 is required for triple-negative breast cancer cell invasion and survival
189. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
190. Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial
191. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer
192. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies
193. Targeting Epigenetic Modifications for the Treatment and Prevention of Breast Cancer
194. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
195. Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy
196. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial
197. Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and therapeutic individualization
198. 62 - Human Immunodeficiency Virus (HIV) Infection and Cancer
199. RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium
200. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.